

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-31. (Cancelled).

32. (Currently amended) A method for the treatment of diseases caused by traumatic or compression injuries to nervous tissues ~~or to the spinal cord~~, the method comprising the step of administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb₁, its metabolites and salts thereof.

33. (Currently amended) The method of claim 32, wherein the pharmaceutical composition is capable of suppressing the secondary degeneration of the nervous tissues caused by traumatic or compression injuries to the nervous tissues ~~or to the spinal cord~~.

34. (Currently amended) The method of claim 33, wherein ~~the secondary degeneration of the nervous tissues is caused by a spinal cord injury~~ the nervous tissues are spinal cords.

35. (Currently amended) The method of claim 32, wherein the therapeutic agent is capable ameliorating paralysis or paraplegia caused by traumatic or compression injuries to the nervous tissues.

36. (Currently amended) The method of claim 35, wherein ~~the paralysis or paraplegia is caused by a spinal cord injury~~ nervous tissues are spinal cords.

37. (Cancelled)

38. (Previously Presented) The method of claim 32, wherein the pharmaceutical composition is capable of suppressing the secondary degeneration of the nervous tissues caused by demyelination.

39. (Previously Presented) The method of claim 38, wherein the pharmaceutical composition is capable of suppressing apoptosis or apoptosis-like cell death of oligodendrocytes.

40. (Previously Presented) The method of claim 32, wherein the pharmaceutical composition is administered intravenously to the patient.

41. (Previously Presented) The method of claim 32, wherein the pharmaceutical composition is administered in a single intravenous infusion or in a continuous intravenous infusion to the patient.

42. (Previously Presented) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition provides a concentration of ginsenoside Rb₁, its metabolites or salts thereof to the extracellular fluid in lesion at a concentration of 1 ng/ml or less.

43. (Previously Presented) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition provides a concentration of ginsenoside Rb₁, its metabolites or salts thereof to the extracellular fluid in lesion at a concentration of 1 pg/ml or less.

44. (Previously Presented) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition provides a

concentration of ginsenoside Rb₁, its metabolites or salts thereof to the extracellular fluid in lesion at a concentration of 100 fg/ml or less.

45-51. (Cancelled).

52. (New) The method of claim 32, wherein the diseases caused by traumatic or compression injuries to the nervous tissues comprise spinal cord injury, head injury, neurotrauma, cerebral hemorrhage, subarachnoid hemorrhage, peripheral nerve injuries, Parkinson's Disease, demyelinating diseases, retinal detachment, herniation of intervertebral disks, spinal canal stenosis, spondylolysis, slipping diseases, cervical spondylolysis, ossification of the posterior longitudinal ligament or facial nerve paralysis.

53. (New) The method of claim 32, wherein the nervous tissues are spinal cords.